Literature DB >> 7947929

Enhancing effect of ATP on intracellular adriamycin penetration in human ovarian cancer cell lines.

R Maymon1, B Bar-Shira Maymon, M Cohen-Armon, M Holtzinger, J Leibovici.   

Abstract

Ovarian cancer has the highest mortality rate of all gynecological malignancies probably due to the evolution of clones resistant to cytotoxic drugs. Exploring possibilities to overcome such resistance constitutes a challenge in this study. We present the effect of adenosine triphosphate (ATP), serving as a chemosensitizer, in combination with adriamycin on three human ovarian cancer cell lines of epithelial origin, OC-109, OC-238 and OC-7-NU, obtained from malignant ascites of different patients, and were proven to be tumorigenic in nude mice. The three lines differ in their sensitivity to the ATP-induced increase in adriamycin accumulation. FACS analysis showed a pronounced increase in intracellular adriamycin accumulation after treatment with various concentrations of ATP. In the OC-238 line, a 50.1% increase was observed at a low ATP concentration (200 microM), whereas higher concentrations (400 microM and 500 microM) were needed to obtain an increase in ADR accumulation of 30% with the other two lines. Our study demonstrates that ATP improves the penetration of adriamycin at the neoplastic cellular level. Furthermore, our results may indicate that intratumoral ATP may serve as an alternative chemosensitizer which lacks the deleterious side effects of other chemosensitizing options.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7947929     DOI: 10.1016/0304-4165(94)90038-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  4 in total

1.  Contribution of intracellular ATP to cisplatin resistance of tumor cells.

Authors:  Verena Schneider; Michaela L Krieger; Gerd Bendas; Ulrich Jaehde; Ganna V Kalayda
Journal:  J Biol Inorg Chem       Date:  2012-11-25       Impact factor: 3.358

Review 2.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

Review 3.  Adenosine triphosphate: established and potential clinical applications.

Authors:  H J Agteresch; P C Dagnelie; J W van den Berg; J H Wilson
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

4.  Phase II study of intravenous adenosine 5'-triphosphate in patients with previously untreated stage IIIB and stage IV non-small cell lung cancer.

Authors:  C M Haskell; E Mendoza; K M Pisters; F V Fossella; R A Figlin
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.